Nanobiotix Reports Strong FY2025 Financials, Extends Cash Runway to 2028, and Advances Clinical Pipeline

summarizeSummary

Nanobiotix reported significantly improved full-year 2025 financial results, including a 65% reduction in net loss and an extended cash runway into early 2028, driven by non-dilutive financing and reduced R&D obligations. The company also highlighted substantial clinical and operational progress across its oncology platforms.

check_boxKey Events

• Strong Financial Performance

  Reported a 65% reduction in net loss to €24.0 million for FY2025 and a significant increase in revenue to €32.6 million, compared to a negative €7.2 million in 2024.

• Extended Cash Runway

  Secured non-dilutive royalty financing of up to $71 million, with $50 million already received, extending the cash runway into early 2028.

• Clinical Pipeline Advancement

  Progressed lead oncology programs for JNJ-1900 (NBTXR3) in head and neck and lung cancers, with positive clinical data reported across multiple tumor types including esophageal, pancreatic, and melanoma.

• New Platform Development

  Advanced the Curadigm Nanoprimer platform with four new patent applications filed and the launch of Chemistry, Manufacturing, and Controls (CMC) activities.

auto_awesomeAnalysis

This 6-K provides a highly positive and comprehensive update for Nanobiotix. The significant reduction in net loss and the extension of the cash runway into early 2028, secured through a non-dilutive royalty financing and reduced R&D obligations, substantially de-risk the company's financial position. This financial stability is critical for a clinical-stage biotech. Furthermore, the continued progress of its lead oncology programs, positive clinical data across multiple tumor types, and the advancement of its next-generation platform demonstrate strong operational execution. Investors should view this filing as a strong signal of improved financial health and continued pipeline momentum, potentially reducing concerns about future dilution and supporting long-term growth prospects. This filing also confirms the concurrent filing of the company's annual report on Form 20-F.